Roctavian

BioMarin, Rare disease, pipeline update, Roctavian, gene therapy, hemophilia A, Pipeline addition

BioMarin R&D chief reveals two new pipeline candidates and strategy to sustain innovation

Anika Sharma

BioMarin, the California-based biotech giant, is embarking on a mission to create its most robust pipeline in history, with a ...

BioMarin's Roctavian_ FDA Approves Hemophilia A Gene Therapy with Positive Reception from Physician | pharmtales

BioMarin’s Roctavian: FDA Approves Hemophilia A Gene Therapy with Positive Reception from Physician

SG Tylor

Source – BioMarin BioMarin’s Roctavian, a gene therapy for severe hemophilia A, has received FDA approval after initial rejection in ...